<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Anti-angiogenic therapy became a standard care of advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Since the most frequent genetic alteration of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is KRAS mutation we have analyzed its effect on the efficacy of Avastin treatment </plain></SENT>
<SENT sid="2" pm="."><plain>Since 2008 we have determined the KRAS status of 575 patients with colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> using a sensitive screening method and sequencing </plain></SENT>
<SENT sid="3" pm="."><plain>In our database the frequency of KRAS mutation in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is 37% (codon 12: 31% followed by codon 13: 6%) </plain></SENT>
<SENT sid="4" pm="."><plain>We have examined the effect of KRAS status on the efficacy of Avastin treatment in 35 patients </plain></SENT>
<SENT sid="5" pm="."><plain>Progression-free survival of KRAS mutant patients was highly similar to that of <z:mp ids='MP_0002169'>wild-type</z:mp> patients using log-rank test (9.2+/-5.5 months versus 8.7+/-5.7 months, respectively) </plain></SENT>
<SENT sid="6" pm="."><plain>Our data support those observations that KRAS status of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> does not interfere with the efficacy of Avastin treatment </plain></SENT>
</text></document>